[Allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia--recent progress].
Allogeneic stem cell transplantation represents the most active form of anti-leukemic therapy in acute myeloid leukemia (AML). Advances in the transplant technology, availability of hematopoietic stem cells and supportive care not only have resulted in improved outcomes but also expanded the transplant options. However, post-transplant relapse and transplant-related mortality, especially those associated with allo-immune reaction after transplantation, remain as the leading causes of failure of this therapeutic approach. This review is going to focus on the recent progress to selectively enhance the anti-AML activity of conditioning and post-transplant allo-immune reaction.
Division of Hematology, Department of Medicine, Keio University School of Medicine.
Shinichiro
S
Okamoto
D000617:Aminoglycosides / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000079982:Gemtuzumab; D020544:Graft vs Leukemia Effect; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods / Q000639:trends; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D019172:Transplantation Conditioning / Q000379:methods / Q000639:trends; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018796:Immunoconjugates; D000079982:Gemtuzumab